Beam Therapeutics Inc.
BEAM
$25.17
-$0.15-0.59%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 1,076.62% | 14.55% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 1,076.62% | 14.55% | |||
| Cost of Revenue | -9.56% | 7.87% | |||
| Gross Profit | 114.82% | -7.27% | |||
| SG&A Expenses | 20.71% | -0.44% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -3.63% | 6.14% | |||
| Operating Income | 86.24% | -5.54% | |||
| Income Before Tax | 316.71% | -10.20% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 316.71% | -10.20% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 316.71% | -10.20% | |||
| EBIT | 86.24% | -5.54% | |||
| EBITDA | 90.29% | -5.79% | |||
| EPS Basic | 316.08% | -9.58% | |||
| Normalized Basic EPS | 309.41% | -10.23% | |||
| EPS Diluted | 311.86% | -9.58% | |||
| Normalized Diluted EPS | 305.32% | -10.23% | |||
| Average Basic Shares Outstanding | 0.30% | 0.56% | |||
| Average Diluted Shares Outstanding | 2.30% | 0.56% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||